Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)

NCT05074810 is registered in ClinicalTrials.gov with Verastem, Inc. as lead sponsor.

NCT NCT05074810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05074810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Verastem, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 12, 2022
Completion date
April 30, 2027
Enrollment
153 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

kras activating mutation, non small cell lung cancer